Skip to main content
ProPeptideGuide

Editorial updates

Journal

Dated editorial updates on peptide regulation, research, and access. Each entry follows the same sourcing standard as our reference pages and links out to the peptide guides it references.

  1. editorial, evidence-review, safety, regulatory, nad

    One molecule, three price tags: NMN, NR, and the $1,000 NAD+ drip, compared

    The NAD+ economy sells three routes to the same target: a $30 bottle of NMN, a canister of nicotinamide riboside, and an IV infusion that can run $1,000 a session. A January 2026 head-to-head trial, an October 2025 Nature Metabolism review, and the FDA's first Class I recall in this market now let us rank the three routes against the evidence — and the ranking runs exactly opposite to the price list.

    Read entry →

  2. editorial, evidence-review, safety, regulatory, gh-secretagogues

    The stack peptide clinics actually sell: CJC-1295 + ipamorelin, and the evidence behind it

    CJC-1295 with ipamorelin is the default 'growth hormone peptide protocol' at anti-aging and telehealth clinics. The complete human evidence base is four small studies, the newest from 2014, none showing a clinical outcome benefit — and FDA advisory committees voted against both compounds in late 2024. An evidence review of the most-sold stack in the peptide economy.

    Read entry →

  6. editorial, glp-1, obesity, regulatory, access

    Retatrutide posted the biggest weight-loss numbers yet — and you still can't legally buy it anywhere

    Retatrutide, Eli Lilly's GLP-1/GIP/glucagon triple agonist, just posted the largest weight-loss figures ever recorded for the drug class in Phase 3 — up to roughly 30%. It is also investigational in every country on earth, with no lawful way to buy it. Here is who makes it, where the only legal access exists, and how people are actually getting it.

    Read entry →